Nuvectis Pharma, Inc. (NASDAQ:NVCT)
| Market Cap | $666.80M+218.9% |
| Revenue (ttm) | $0 |
| Net Income | -$50.45M-98.8% |
| EPS | -$1.89-40.0% |
| Shares Out | 34.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 301,603 |
| Open | $19.81 |
| Previous Close | $19.84 |
| Day's Range | $19.05 - $20.09 |
| 52-Week Range | $5.77 - $29.28 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $37.33(+92.52%) |
| Earnings Date | Feb 10, 2027 |
About NVCT
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating NVCT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 10, 2027Earnings report
$NVCT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NVCT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NVCT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NVCT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NVCT Revenue by Segment
| Segment Loss | $30.07M | 54.26% |
| License Fees | $21.80M | 39.34% |
| Professional Fees | $2.29M | 4.12% |
| Insurance and other | $722.00K | 1.30% |
| Manufacturing | $545.00K | 0.98% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NVCT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NVCT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NVCT
| IWMiShares Russell 2000 ETF | $11.00M |
| VTIVanguard Morningstar Total Stock Market ETF | $9.47M |
| VXFVanguard Extended Market ETF | $4.40M |
| IWOiShares Russell 2000 Growth ETF | $4.00M |
| VTWOVanguard Russell 2000 ETF | $2.27M |
| FESMFidelity Enhanced Small Cap ETF | $2.13M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NVCT’s recent data — informational, not investment advice
